1.70
+0.02(+1.19%)
Currency In USD
| Previous Close | 1.68 |
| Open | 1.67 |
| Day High | 1.7 |
| Day Low | 1.65 |
| 52-Week High | 2.97 |
| 52-Week Low | 0.98 |
| Volume | 8,710 |
| Average Volume | 19,609 |
| Market Cap | 68.54M |
| PE | -7.73 |
| EPS | -0.22 |
| Moving Average 50 Days | 1.56 |
| Moving Average 200 Days | 1.8 |
| Change | 0.02 |
If you invested $1000 in BeyondSpring Inc. (BYSI) since IPO date, it would be worth $101.19 as of June 07, 2025 at a share price of $1.7. Whereas If you bought $1000 worth of BeyondSpring Inc. (BYSI) shares 5 years ago, it would be worth $94.71 as of June 07, 2025 at a share price of $1.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring”
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a p
BeyondSpring Files 2024 Annual Report on Form 10-K
GlobeNewswire Inc.
Mar 27, 2025 11:05 AM GMT
FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed i